Pharmaceuticals in United States
90 verified figures for United States, covering 80 indicators from 7 primary sources. Every figure links to the report it came from.
The short version
Key takeaways
- Novel drug approvals in United States stood at 46 in 2025 (FDA). FDA ↗ T1 Official
- Pharmaceutical and medicine manufacturing net sales in United States totalled 685,744 million USD in 2022 (NCSES). NCSES ↗ T1 Official
- COVID-19 vaccines and therapeutics spending decline in United States came in at 4 billion USD in 2025 (IQVIA). IQVIA ↗
- Net medicine spending in United States totalled 606 billion USD in 2025 (IQVIA). IQVIA ↗
- Net medicine spending increase in United States came in at 58 billion USD in 2025 (IQVIA). IQVIA ↗
- Pharmaceutical and medicine manufacturing R&D funded by domestic companies in United States stood at 2,104 million USD in 2023 (NCSES). NCSES ↗ T1 Official
- Pharmaceutical and medicine manufacturing R&D funded by foreign companies in United States stood at 9 billion USD in 2023 (NCSES). NCSES ↗ T1 Official
- Medicare patient out-of-pocket medicine cost decline in United States came in at 638 million USD in 2025 (IQVIA). IQVIA ↗
- Patient out-of-pocket medicine cost increase in United States came in at 6 billion USD in 2025 (IQVIA). IQVIA ↗
- Patient out-of-pocket medicine costs in United States averaged 110 billion USD in 2025 (IQVIA). IQVIA ↗
The complete table
Pharmaceuticals data for United States
Every row links to its own page with the full source, verbatim quote and citation.
90 data points across 80 indicators. Each line shows the latest value; open a line for earlier periods and forecasts.
IndicatorPeriodValueSourceType
Approved immunotherapy drugs (multi-year total)2010–202530PhRMAT22025actual→
Biopharmaceutical R&D expenditure (multi-year total)2015–2024900 billion USDPhRMAT22024actual→
Biosimilar biological product approvals202418FDAT12024actual→
Botanical drug products approved as prescription drugsas of 3 Sep 20264FDAT12026actual→
Cell and gene therapy spending share by geography202362%IQVIA2023actual→
Clinical development regulatory approval rateend of 202512%PhRMAT22025estimate→
Clinical trial country use share2021–202316%IQVIA2023actual→
Company operating locationsas of 20 Aug 202624RocheT22026actual→
Compound annual net medicine spending growth2020–20259.3%IQVIA2025actual→
COVID-19 vaccines and therapeutics spending decline20254 billion USDIQVIA2025actual→
Cumulative biopharmaceutical R&D expenditure2000–20251 trillion USDPhRMAT22025actual→
Cumulative biosimilar approvals2015–202460FDAT12024actual→
Cumulative five-year novel active substance launches +1 more 2021–2025270IQVIA2025actual→
Expected annual novel active substance launches (lower bound)2026–203050IQVIA2030forecast→
Expected annual novel active substance launches (upper bound)2026–203055IQVIA2030forecast→
First-cycle novel drug approvals202437FDAT12024actual→
First-year new prescriptions for novel medicines (multi-year total)2020–20247 millionIQVIA2024actual→
Five-year cumulative medicine use growth2020–202513%IQVIA2025actual→
Forecast list-price medicine spending growth lower bound2026–20306%IQVIA2030forecast→
Forecast list-price medicine spending growth upper bound2026–20309%IQVIA2030forecast→
Forecast net medicine spending growth lower bound2026–20304.5%IQVIA2030forecast→
Forecast net medicine spending growth upper bound2026–20307.5%IQVIA2030forecast→
GIP/GLP-1 agonist spending growth contribution202514 billion USDIQVIA2025actual→
Health sector research and development investment growth rate20247.1%European CommissionT12025actual→
Interchangeable biosimilar approvals20249FDAT12024actual→
Life sciences and patient organization deal valueas of 5 Oct 20232.4 billion USDIQVIA2023estimate→
Life sciences and patient organization dealsas of 5 Oct 2023700IQVIA2023estimate→
Medicare patient out-of-pocket medicine cost decline2025638 million USDIQVIA2025actual→
Medicare patient out-of-pocket medicine cost decline rate20252.2%IQVIA2025actual→
Net medicine spending +1 more 2025606 billion USDIQVIA2025actual→
Net medicine spending growth202510.6%IQVIA2025actual→
Net medicine spending increase202558 billion USDIQVIA2025actual→
Non-retail share of prescription medicine use202516%IQVIA2025actual→
Novel active substance launches +1 more 202553IQVIA2025actual→
Novel active substance launches (multi-year total) +1 more 2021–2025270IQVIA2025actual→
Novel active substance launches growth rate +1 more 2021–202517%IQVIA2025actual→
Novel antibiotic approvals20243FDAT12024actual→
Novel drug approvals meeting user fee goal dates202447FDAT12024actual→
Novel drug approvals using expedited programs202433FDAT12024actual→
Novel drugs approved first in domestic market202434FDAT12024actual→
Novel medicine prescription fill rate2020–202435%IQVIA2024actual→
Novel medicine prescription patient abandonment rate2020–202417%IQVIA2024actual→
Novel medicine prescription payer rejection rate2020–202449%IQVIA2024actual→
Novel medicine prescription unfilled rate2020–202465%IQVIA2024actual→
Obesity-approved GIP and GLP-1 agonist medicine spending growth20259.6 billion USDIQVIA2025actual→
Oncology novel active substance launches (multi-year total)2020–202485IQVIA2024actual→
Orphan drug approvals202426FDAT12024actual→
Patient out-of-pocket medicine cost increase20256 billion USDIQVIA2025actual→
Patient out-of-pocket medicine costs2025110 billion USDIQVIA2025actual→
Pharmaceutical and medicine manufacturing company-funded R&D2023114,225 million USDNCSEST12023actual→
Pharmaceutical and medicine manufacturing externally funded R&D202311,761 million USDNCSEST12023actual→
Pharmaceutical and medicine manufacturing government-funded R&D2023549 million USDNCSEST12023actual→
Pharmaceutical and medicine manufacturing net sales2022685,744 million USDNCSEST12022actual→
Pharmaceutical and medicine manufacturing R&D funded by domestic companies20232,104 million USDNCSEST12023actual→
Pharmaceutical and medicine manufacturing R&D funded by foreign companies20239 billion USDNCSEST12023actual→
Pharmaceutical and medicine manufacturing R&D funded by other external sources202379 million USDNCSEST12023actual→
Pharmaceutical and medicine manufacturing R&D intensity +1 more 202317.8%NCSEST12023actual→
Pharmaceutical and medicine manufacturing total R&D performance +1 more 2023125,986 million USDNCSEST12023actual→
Pharmaceutical corporate employmentas of 20 Aug 202625,000RocheT22026estimate→
Pharmaceutical manufacturing employment creation +1 more end of 2031250RocheT22026forecast→
Pharmaceutical manufacturing facility capital investmentas of 20 Aug 2026750 million USDRocheT22026forecast→
Pharmaceutical manufacturing sitesas of 20 Aug 202613RocheT22026actual→
Pharmaceutical research and development sitesas of 20 Aug 202615RocheT22026actual→
Prescription medicine use2025210 billion days of therapyIQVIA2025actual→
Prescription medicine use growth20251.5%IQVIA2025actual→
Projected net medicine spending increase2025–2030200 billion USDIQVIA2030forecast→
Reference products with biosimilar approvals20248FDAT12024actual→
Retail prescription drug volume compound annual growth rate2020–20252.4%IQVIA2025actual→
Retail share of prescription medicine use202584%IQVIA2025actual→
Sales growth at constant exchange ratesQ1 20266%RocheT22026actual→
Sales growth in Swiss francsQ1 2026-3%RocheT22026actual→
Share of first-cycle novel drug approvals202474%FDAT12024actual→
Share of novel drug approvals meeting user fee goal dates202494%FDAT12024actual→
Share of novel drug approvals using expedited programs202466%FDAT12024actual→
Share of novel drugs approved first in domestic market202468%FDAT12024actual→
T-cell engager market size for multiple myeloma203210 billion USDGSKT22032forecast→
Primary documents
Sources
| Document | Publisher | Authority tier | Published | Accessed | Locator | Data points |
|---|---|---|---|---|---|---|
| The 2025 EU Industrial R&D Investment Scoreboard Press release | European Commission | T1 Official | 22 Dec 2025 | 17 Sep 2026 | EU: Health and energy sectors shine in a year of slowdown | 1 |
| Business R&D Performance in the United States Increases to $722 Billion in 2023 Press release | NCSES | T1 Official | — | 17 Sep 2026 | Table 2. Funds spent for business R&D performed in the United States, by source of funds, selected industry, and company size: 2023; R&D Performance, by Type of R&D, Industry Sector, and Source of Funding; Sales, R&D Intensity, and Employment of Companies That Performed or Funded R&D | 8 |
| Discovery: R&D Activity and Research Publications Press release | NCSES | T1 Official | — | 17 Sep 2026 | Industries That Perform the Most U.S. Business R&D; Table DISC-3. Domestic net sales, R&D, and R&D-to-sales ratio for companies that performed or funded U.S. business R&D, by selected industry: 2022 | 3 |
| CDER Brings Many Safe and Effective Therapies to Patients and Consumers in 2024 Press release | FDA | T1 Official | — | 17 Sep 2026 | A Record Year for Biosimilar Approvals; CDER’s Effectiveness Bringing New Therapies to Market; Creating a Yearly Snapshot for Approvals | 15 |
| FDA Seeks Public Input to Advance Development of Botanical Drug Products Press release | FDA | T1 Official | — | 17 Sep 2026 | FDA Seeks Public Input to Advance Development of Botanical Drug Products | 1 |
| Novel Drug Approvals for 2025 Press release | FDA | T1 Official | — | 17 Sep 2026 | FDA Novel Drug Therapy Approvals for 2025 | 1 |
| Novel Drug Approvals for 2024 Press release | FDA | T1 Official | — | 17 Sep 2026 | FDA Novel Drug Therapy Approvals for 2024 | 1 |
| GSK to acquire potential best-in-class T cell-engager (TCE) for multiple myeloma from Chimagen Biosciences Press release | GSK | T2 National | — | 15 Sep 2026 | Deal aligned to GSK’s portfolio in blood cancer and approach of acquiring differentiated assets with validated targets | 1 |
| Research & Development Press release | PhRMA | T2 National | — | 17 Sep 2026 | Revolutionizing Cancer Care with Immunotherapy; Policy Framework; Progress toward New Medicines and Vaccines | 4 |
| Roche’s US subsidiary Genentech announces manufacturing expansion in the United States Press release | Roche | T2 National | 20 Aug 2026 | 15 Sep 2026 | Roche’s US subsidiary Genentech announces manufacturing expansion in the United States | 7 |
| [Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a... Press release | Roche | T2 National | 23 Jul 2026 | 15 Sep 2026 | Group results | 2 |
| U.S. Medicine Use Trends 2026 Press release | IQVIA | T3 Research | — | 15 Sep 2026 | Other Findings; Key Findings | 34 |
| Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios Press release | IQVIA | T3 Research | — | 15 Sep 2026 | Global cell and gene therapy spending and share by geography | 1 |
| Rethinking Clinical Trial Country Prioritization Press release | IQVIA | T3 Research | — | 15 Sep 2026 | Country utilization is heavily consolidated in U.S., China and Western European countries | 1 |
| Global R&D Trends 2026 Press release | IQVIA | T3 Research | — | 15 Sep 2026 | Exhibit 33: Novel active substances (NAS) launched globally and in selected countries, 2006–2025 | 3 |
| Global R&D Trends 2026 Press release | IQVIA | T3 Research | — | 15 Sep 2026 | Exhibit 33: Novel active substances (NAS) launched globally and in selected countries, 2006–2025 | 4 |
| Supporting patients through research collaboration Press release | IQVIA | T3 Research | — | 16 Sep 2026 | Key findings: | 2 |
| Global Oncology Trends 2025 Press release | IQVIA | T3 Research | — | 16 Sep 2026 | Other Findings | 1 |
Report snapshots are retained internally for verification only and are never redistributed. Where a figure comes from a paywalled report, only the number published in its public summary is recorded.
All 90 collected records for United States are published as verified.
Cite & reuse
Cite this page
Data on this page is published under CC BY 4.0. You may reuse it, including commercially, provided you attribute it. Each figure's own page carries APA, MLA, Chicago and BibTeX citations naming its original publisher.
StatOrigin. (2026). Pharmaceuticals in United States: statistics. Retrieved from https://statorigin.org/industries/pharmaceuticals/united-states